Search - tctmd.com

Displaying 1 - 20 of 25

Sort: Relevancy | Date

LAAO Doesn’t Match Medical Therapy for High-risk AF Patients: CLOSURE-AF

News Conference News AHA 2025

LAAO Doesn’t Match Medical Therapy for High-risk AF Patients: CLOSURE-AF

November 09, 2025

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

News Conference News AHA 2025

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

November 08, 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

News Conference News ESC 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

September 01, 2025

Positive Results With Volt Pulsed-Field Ablation System

News Conference News EHRA 2025

Positive Results With Volt Pulsed-Field Ablation System

April 07, 2025

EXPANDed: Atrial Secondary MR Patients Get Clinical Benefit From TEER

News Conference News HFSA 2024

EXPANDed: Atrial Secondary MR Patients Get Clinical Benefit From TEER

October 03, 2024

Polymer Mitral Valve Shows Well Early, but Long-term Data Key

News Conference News NY Valves 2024

Polymer Mitral Valve Shows Well Early, but Long-term Data Key

Michael O'Riordan

June 12, 2024

DANPACE II: Reducing Atrial Pacing Doesn’t Prevent AF in Sinus Node Disease

News Conference News ESC 2023

DANPACE II: Reducing Atrial Pacing Doesn’t Prevent AF in Sinus Node Disease

August 30, 2023

First-line Ablation Reduces AF Progression, Boosts Quality of Life

News Conference News AHA 2022

First-line Ablation Reduces AF Progression, Boosts Quality of Life

November 07, 2022

More Support for Single Antiplatelet Therapy After TAVI

News Conference News TVT 2022

More Support for Single Antiplatelet Therapy After TAVI

Michael O'Riordan

June 10, 2022

MitraClip Helps for Atrial Functional MR: MITRA-TUNE

News Conference News EuroPCR 2022

MitraClip Helps for Atrial Functional MR: MITRA-TUNE

Michael O'Riordan

May 19, 2022

Registry Shows Watchman FLX Beating First-Gen Device for Early LAAO Outcomes

News Conference News HRS 2022

Registry Shows Watchman FLX Beating First-Gen Device for Early LAAO Outcomes

May 02, 2022

Managing AF Patients Undergoing PCI—Some Lingering Questions

News Conference News ACC 2022

Managing AF Patients Undergoing PCI—Some Lingering Questions

Michael O'Riordan

April 12, 2022

Amulet LAA Closure Device Has Fewer Leaks Than Watchman: Does It Matter?

News Conference News TCT 2021

Amulet LAA Closure Device Has Fewer Leaks Than Watchman: Does It Matter?

November 06, 2021

AV Junction Ablation Plus CRT Cuts Deaths in Permanent AF Subset

News Conference News ESC 2021

AV Junction Ablation Plus CRT Cuts Deaths in Permanent AF Subset

September 01, 2021

A-fib Screening Yields Promising Results, But Uncertainty Remains: mSToPS and VITAL-AF

News Conference News

A-fib Screening Yields Promising Results, But Uncertainty Remains: mSToPS and VITAL-AF

November 19, 2020

Rivaroxaban an Option for Patients with Bioprosthetic Mitral Valves and A-fib

News Conference News AHA 2020

Rivaroxaban an Option for Patients with Bioprosthetic Mitral Valves and A-fib

November 14, 2020

LAAO Registry: Safety of Watchman Looks Good in First Years of Rollout

News Conference News ACC 2020

LAAO Registry: Safety of Watchman Looks Good in First Years of Rollout

April 06, 2020

Optimal Time to Start Anticoagulation After Stroke Remains Unclear

News Conference News ISC 2020

Optimal Time to Start Anticoagulation After Stroke Remains Unclear

February 27, 2020

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

September 26, 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

News Conference News ESC 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

September 11, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.